Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by L & S Advisors Inc

L & S Advisors Inc lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 66.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,542 shares of the medical research company's stock after selling 5,132 shares during the period. L & S Advisors Inc's holdings in Thermo Fisher Scientific were worth $1,323,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Legacy Investment Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at about $26,000. Barrett & Company Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $28,000. FPC Investment Advisory Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. Pillar Financial Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Finally, Missouri Trust & Investment Co purchased a new position in Thermo Fisher Scientific in the 4th quarter valued at $29,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. UBS Group boosted their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research report on Friday, January 31st. Wells Fargo & Company lifted their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Bank of America reduced their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a research note on Friday, December 13th. Scotiabank lifted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a research report on Monday, February 3rd. Finally, Citigroup lowered their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $653.23.

Remove Ads

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Down 3.0 %

NYSE TMO traded down $15.09 during trading hours on Tuesday, hitting $482.51. 1,837,520 shares of the company were exchanged, compared to its average volume of 1,620,453. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm has a market cap of $182.03 billion, a price-to-earnings ratio of 29.19, a PEG ratio of 2.99 and a beta of 0.79. The company has a 50 day moving average of $540.37 and a two-hundred day moving average of $551.02. Thermo Fisher Scientific Inc. has a 52-week low of $481.47 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. The ex-dividend date is Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.36%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.